



**Proteomics International**

LABORATORIES LTD

ASX Release

18 June 2018

ASX code: PIQ

## **Proteomics International signs licensing deal with Patia Biopharma for PromarkerD predictive test for diabetic kidney disease in Mexico**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed a licence agreement for its world-leading PromarkerD predictive test for diabetic kidney disease with Patia BioPharma, a Mexican biotech company focused on promoting personalised preventive medicine across Latin America. The deal was brokered by philanthropic organisation the Carlos Slim Foundation.

### **Highlights**

- **PromarkerD test to be launched in Mexico in an exclusive deal with Patia Biopharma brokered by the Carlos Slim Foundation**
- **Agreement comes three weeks after licensing deal for PromarkerD in the US**
- **Diabetes is responsible for one in seven deaths in Mexico, killing more people than cancer**
- **Mexico has one of the highest rates of diabetes in the world, with 13 million adults suffering from the condition**
- **The test will be commercially available to private hospitals, private clinics, government hospitals and Carlos Slim Foundation programs**

Diabetes is Mexico's second biggest killer and in 2016 the Mexican health ministry declared the diabetes epidemic a national health emergency, and promised extra funding for the detection and treatment of the disease.

The exclusive, multi-year, royalty based licence agreement will see Patia develop and commercialise the PromarkerD mass spectrometry "Laboratory Developed Test" (LDT) through its network of laboratories in Mexico. All testing will be performed in association with Patia's partner, Clinica Ruiz Laboratories, an ANAB-accredited laboratory. The LDT permits fast adoption of a new test in advanced markets.

Through Patia's network the test will initially be introduced to private hospitals and private clinics, and then expanded into government hospitals and Carlos Slim Foundation programs. First sales are anticipated to be in four to six months.

"PromarkerD is a break-through test that allows us to pre-empt diabetic kidney disease, one of the most costly complications of diabetes," said Laureano Simon, PhD, Chief Executive Officer of Patia. "This predictive test will let us intervene early and prescribe treatments to prevent the disease, and help reverse the growing impact of diabetes on public health in Mexico."

Diabetes is responsible for one in seven deaths in Mexico, killing more people than cancer, and the condition is second only to cardiovascular diseases as the leading cause of mortality. Ten percent of people living with diabetes are expected to suffer a rapid decline in kidney function within four years, leading to dialysis or kidney transplant.

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

The World Health Organisation believes Mexico has one of the highest rates of diabetes in the world, greater even than the US. Already Mexico is home to 13 million adults with diabetes, or three per cent of the world's diabetics, and scientists predict that if current trends continue as many as one in two people in Mexico could be diagnosed with diabetes in their lifetime.

Proteomics International managing director Dr Richard Lipscombe said it was fantastic to be working with Patia, Clinica Ruiz Laboratories and the Carlos Slim Foundation to improve the lives of people with diabetes in Mexico. "This agreement is another important milestone in the roll-out of PromarkerD globally," he added.

The deal with Patia Biopharma marks the third licensing agreement for PromarkerD. It comes three weeks after Proteomics International announced it had secured a deal to launch PromarkerD in the United States, in partnership with precision medicine and diagnostic services laboratory PrismHealthDx, Inc. (PHDx). An earlier contract with Omics Global Solutions and Macrotech saw the test launched in Central America in the Dominican Republic in March.

Together the three deals are expected to drive demand for PromarkerD in other jurisdictions, and Proteomics International continues its discussions with diagnostic and pharmaceutical companies in multiple countries.

PromarkerD is a simple blood test that uses a unique protein 'fingerprint' to provide an early detection of the onset of diabetic kidney disease. PromarkerD is the first test able to predict the onset of diabetic kidney disease, warning of a decline in kidney function up to four years in advance.

ENDS

#### **About PromarkerD ([www.PromarkerD.com](http://www.PromarkerD.com))**

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented in 2017 at the American Diabetes Association Annual Scientific Sessions [ASX: 10 June 2017] and published in the prestigious journal Diabetes Care [ASX: 6 September 2017], PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by the global research house Frost & Sullivan in its report titled Biomarkers Enabling Diabetes and Obesity Management [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

Further information is available through the PromarkerD web portal.

#### **About Patia Biopharma ([www.patiadiabetes.com](http://www.patiadiabetes.com))**

Patia Biopharma is a Mexican company focused on promoting personalised preventive medicine across Mexico, Latin America and worldwide. Patia offers the medical community a vast array of genomic, metabolomic and proteomic tests for risk assessment and early diagnosis, which support early interventions in patients with diabetes.

#### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

**For further information please contact:**

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Susan Fitzpatrick-Napier  
[Public Relations & Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)